Next Generation Cytopathology: Current Status and Future Prospects

Guest Editor:

Dr. Chien-Chin Chen
1. Department of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan, Taiwan
2. Department of Pathology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan
3. Department of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan
4. Ph.D. Program in Translational Medicine, Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Tainan, Taiwan

Deadline for manuscript submissions:
31 August 2024

Message from the Guest Editor

Cytopathology is a key specialty in identifying and managing various illnesses, and recent advances have been astounding. The advancement of liquid-based cytology and molecular testing has enabled earlier and more accurate diagnoses and tailored medicines based on genetic abnormalities, improving outcomes for numerous individuals.

Overall, the area of cytopathology is primed for further advancement and innovation in the following years, with the potential to improve patient outcomes and save lives. This Special Issue, entitled "Cytopathology: Current Status and Future Prospects," aims to recruit high-quality original articles or comprehensive reviews focusing on cytopathology and advances in the following subjects:

- New insights and experience in international reporting systems;
- Application of new molecular or ancillary testing in cytopathology;
- The utilization of digital pathology;
- Rapid on-site evaluation and potential pitfalls;
- Machine learning models for cytopathology;
- Comprehensive comparison for different methods or interobserver variability.

mdpi.com/si/170957

Special Issue

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us